Stay updated on MG1-MAGEA3 Combo with Pembrolizumab for NSCLC Clinical Trial

Sign up to get notified when there's something new on the MG1-MAGEA3 Combo with Pembrolizumab for NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the MG1-MAGEA3 Combo with Pembrolizumab for NSCLC Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-14T02:02:39.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in the Phase 1/2 clinical trial protocol for treating Non-Small Cell Lung Cancer patients with Ad-MAGEA3 and MG1-MAGEA3 in combination with pembrolizumab, specifying dose escalation criteria and treatment regimens.
    Difference
    0.1%
    Check dated 2024-06-06T16:00:11.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to provide detailed eligibility criteria for trial participants, including specific health conditions and prior treatments required for inclusion. Previously, this section only indicated that no information was provided.
    Difference
    45%
    Check dated 2024-05-22T15:17:49.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.5%
    Check dated 2024-04-30T22:46:57.000Z thumbnail image

Stay in the know with updates to MG1-MAGEA3 Combo with Pembrolizumab for NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the MG1-MAGEA3 Combo with Pembrolizumab for NSCLC Clinical Trial page.